info@marketresearchfuture.com πŸ“ž +1 628 258 0071(US)  πŸ“ž +44 2035 002 764(UK)
Chronic Disease Management Market Research Report - Forecast till 2027

Chronic Disease Management Market Research Report: By Solution (Educational Solution, Implementation Solution, Consulting Solution and others), Delivery Mode (Cloud-Based, On-Premises and Web-Based), Application (Arthritis, Cardiovascular Disease, Cancer, Diabetes and others), End-User (Providers, Payers) and Region (Americas, Europe, Asia-Pacific, Middle East & Africa) - Forecast till 2027

ID: MRFR/HS/0475-HCR | February 2021 | Region: Global | 90 pages

Impact of COVID- 19 on Chronic Disease Management Market


The impact of COVID-19 on the economy will affect not just people’s income but also their health. A team from the Northwell Health COVID-19 Research Consortium and the Feinstein Institutes for Medical Research collected data on the patients from the enterprise EHR reporting database. In the largest study of hospitalized COVID-19 patients in the US, researchers leveraged EHR data to find that hypertension, diabetes, and obesity are key chronic diseases in the acuity of the virus. Researchers found that of the 2,634 patients studied, 56.6 percent had hypertension, 41.7 percent had obesity, and 33.8 percent had diabetes – the most common comorbidities among the research subjects.


Source: Northwell Health COVID-19 Research Consortium, the Feinstein Institutes for Medical Research, MRFR Analysis


According to the Department of Health and Social Care, in England, the treatment and care of people with chronic diseases account for an estimated 70% of total health and social care expenditure. Around one in three of the population currently have at least one long-term health condition. Currently, most of the resources and expenditures are allocated for the mitigation of the pandemic. This is expected to delay the treatment of patients suffering from chronic diseases.


India accounts for approximately one-quarter of the world’s TB burden, with the estimated number of new TB cases in 2018 at 2,800,000. To curb the spread of COVID-19, the Indian Government announced a nationwide lockdown in March 2020. The lockdown is a major hurdle to TB patients seeking health care and may result in a delay in diagnosis, treatment interruptions, and disease transmission in household contacts. Lockdown has also forced many migrant workers to return to their homes, leading to treatment interruption. Many health facilities are turning to the use of digital platforms to make medical care accessible in difficult to reach areas. To eliminate TB by 2025, a greater number of pharmaceutical companies will need to work in congruence with healthcare providers. A study published by researchers at two universities in Taiwan and the Johns Hopkins Bloomberg School of Public Health following the 2002-2004 SARS outbreak suggested that chronic-care hospitalizations for diabetes plummeted during the crisis but skyrocketed afterward. Health experts are worried that similar problems could crop up because of the Covid-19 pandemic.


During Italy's national lockdown for COVID-19, official hospital statistics in the period March 1–27, 2020, showed substantial decrease—ranging from 73% to 88%—in pediatric emergency department visits compared with the same time in 2019 and 2018.  The fall in the number of visits to pediatric emergency departments across five hospitals in Italy.


Source: The Lancet, MRFR Analysis


Startups are pushing to educate people with chronic conditions about COVID-19.



  • Comcast health tech spinout Quil recently unveiled a tool that helps elective surgery patients stay on track until their operations are rescheduled



  • Virta and another diabetes-focused digital health company, Omada, have started hosting webinars and creating special patient groups to keep people informed


Clover is using an algorithm to pinpoint the patients most at risk of infection. Clover’s clinicians are using that to reach out to certain patients and suggest patients avoid places where they would be likely to be exposed to infection

Table of Contents

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Primary Research

3.3. Secondary Research

3.4. Market Size Estimation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

 

6. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET, BY SOLUTION

6.1. Overview

6.2. Educational Solution

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.3. Implementation Solution

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.4. Consulting Solution

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.5. Others

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET, BY DELIVERY MODE

7.1. Overview

7.2. Cloud-Based

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3. On-Premises

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.4. Web Based

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET, BY APPLICATION

8.1. Overview

8.2. Arthritis

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.3. Cardiovascular Disease

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.4. Cancer

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.5. Diabetes

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.6. Others

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

9. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET, BY END-USER

9.1. Overview

9.2. Providers

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

9.3. Payers

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

10. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET, BY REGION

10.1. Overview

10.2. Americas

10.2.1. North America

10.2.1.1. US

10.2.1.2. Canada

10.2.2. Latin America

10.3. Europe

10.3.1. Western Europe

10.3.1.1. Germany

10.3.1.2. France

10.3.1.3. Italy

10.3.1.4. Spain

10.3.1.5. UK

10.3.1.6. Rest of Western Europe

10.3.2. Eastern Europe

10.4. Asia-Pacific

10.4.1. Japan

10.4.2. China

10.4.3. India

10.4.4. Australia

10.4.5. South Korea

10.4.6. Rest of Asia-Pacific

10.5. Middle East & Africa

10.5.1. Middle East

10.5.2. Africa

11. COMPANY LANDSCAPE

11.1. Overview

11.2. Competitive Analysis

11.3. Market Share Analysis

11.4. Major Growth Strategy in the Global Chronic Disease Management Market

11.5. Competitive Benchmarking

11.6. Leading Players in Terms of Number of Developments in the Global Chronic Disease Management Market

11.7. Key developments and Growth Strategies

11.7.1. DELIVERY MODE Launch/ Deployment

11.7.2. Mergers and Acquisitions

11.7.3. Joint Ventures

11.8. Major Players Financial Matrix & Market Ratio

11.8.1. Sales & Operating Income 2020

11.8.2. Major Players R&D Expenditure 2020

11.9. Major Players Capital Market Ratio

12. COMPANY PROFILES

12.1. TriZetto Corporation

12.1.1. Company Overview

12.1.2. Product Overview

12.1.3. Financial Overview

12.1.4. Key Developments

12.1.5. SWOT Analysis

12.1.6. Key Strategies

12.2. Infosys Limited

12.2.1. Company Overview

12.2.2. Product Overview

12.2.3. Financial Overview

12.2.4. Key Developments

12.2.5. SWOT Analysis

12.2.6. Key Strategies

12.3. Pegasystems Inc.

12.3.1. Company Overview

12.3.2. Product Overview

12.3.3. Financial Overview

12.3.4. Key Developments

12.3.5. SWOT Analysis

12.3.6. Key Strategies

12.4. Siemens Healthcare Private Limited

12.4.1. Company Overview

12.4.2. Product Overview

12.4.3. Financial Overview

12.4.4. Key Developments

12.4.5. SWOT Analysis

12.4.6. Key Strategies

12.5. MINES & Associates, Inc.

12.5.1. Company Overview

12.5.2. Product Overview

12.5.3. Financial Overview

12.5.4. Key Developments

12.5.5. SWOT Analysis

12.5.6. Key Strategies

12.6. Allscripts Healthcare Solutions, Inc.

12.6.1. Company Overview

12.6.2. Product Overview

12.6.3. Financial Overview

12.6.4. Key Developments

12.6.5. SWOT Analysis

12.6.6. Key Strategies

12.7. Koninklijke Philips NV

12.7.1. Company Overview

12.7.2. Product Overview

12.7.3. Financial Overview

12.7.4. Key Developments

12.7.5. SWOT Analysis

12.7.6. Key Strategies

12.8. EXL Healthcare

12.8.1. Company Overview

12.8.2. Product Overview

12.8.3. Financial Overview

12.8.4. Key Developments

12.8.5. SWOT Analysis

12.8.6. Key Strategies

12.9. Harmony Information Systems, Inc.

12.9.1. Company Overview

12.9.2. Product Overview

12.9.3. Financial Overview

12.9.4. Key Developments

12.9.5. SWOT Analysis

12.9.6. Key Strategies

12.10. ScienceSoft USA Corporation. (US)

13. APPENDIX

13.1. References

13.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SYNOPSIS, 2020–2027

TABLE 2 GLOBAL CHRONIC DISEASE MANAGEMENT MARKET ESTIMATES & FORECAST, 2020–2027 (USD MILLION)

TABLE 3 GLOBAL CHRONIC DISEASE MANAGEMENT MARKET, BY SOLUTION, 2020–2027 (USD MILLION)

TABLE 4 GLOBAL CHRONIC DISEASE MANAGEMENT MARKET, BY DELIVERY MODE, 2020–2027 (USD MILLION)

TABLE 5 GLOBAL CHRONIC DISEASE MANAGEMENT MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

TABLE 6 GLOBAL CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2020–2027 (USD MILLION)

TABLE 7 GLOBAL CHRONIC DISEASE MANAGEMENT MARKET, BY REGION, 2020–2027 (USD MILLION)

TABLE 8 NORTH AMERICA: CHRONIC DISEASE MANAGEMENT MARKET, BY SOLUTION, 2020–2027 (USD MILLION)

TABLE 9 NORTH AMERICA: CHRONIC DISEASE MANAGEMENT MARKET, BY DELIVERY MODE, 2020–2027 (USD MILLION)

TABLE 10 NORTH AMERICA: CHRONIC DISEASE MANAGEMENT MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

TABLE 11 NORTH AMERICA CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2020–2027 (USD MILLION)

TABLE 12 US: CHRONIC DISEASE MANAGEMENT MARKET, BY SOLUTION, 2020–2027 (USD MILLION)

TABLE 13 US: CHRONIC DISEASE MANAGEMENT MARKET, BY DELIVERY MODE, 2020–2027 (USD MILLION)

TABLE 14 US: CHRONIC DISEASE MANAGEMENT MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

TABLE 15 US: CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2020–2027 (USD MILLION)

TABLE 16 CANADA: CHRONIC DISEASE MANAGEMENT MARKET, BY SOLUTION, 2020–2027 (USD MILLION)

TABLE 17 CANADA: CHRONIC DISEASE MANAGEMENT MARKET, BY DELIVERY MODE, 2020–2027 (USD MILLION)

TABLE 18 CANADA: CHRONIC DISEASE MANAGEMENT MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

TABLE 19 CANADA: CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2020–2027 (USD MILLION)

TABLE 20 LATIN AMERICA: CHRONIC DISEASE MANAGEMENT MARKET, BY SOLUTION, 2020–2027 (USD MILLION)

TABLE 21 LATIN AMERICA: CHRONIC DISEASE MANAGEMENT MARKET, BY DELIVERY MODE, 2020–2027 (USD MILLION)

TABLE 22 LATIN AMERICA: CHRONIC DISEASE MANAGEMENT MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

TABLE 23 LATIN AMERICA: CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2020–2027 (USD MILLION)

TABLE 24 EUROPE: CHRONIC DISEASE MANAGEMENT MARKET, BY SOLUTION, 2020–2027 (USD MILLION)

TABLE 25 EUROPE: CHRONIC DISEASE MANAGEMENT MARKET, BY DELIVERY MODE, 2020–2027 (USD MILLION)

TABLE 26 EUROPE: CHRONIC DISEASE MANAGEMENT MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

TABLE 27 EUROPE: CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2020–2027 (USD MILLION)

TABLE 28 WESTERN EUROPE: CHRONIC DISEASE MANAGEMENT MARKET, BY SOLUTION, 2020–2027 (USD MILLION)

TABLE 29 WESTERN EUROPE: CHRONIC DISEASE MANAGEMENT MARKET, BY DELIVERY MODE, 2020–2027 (USD MILLION)

TABLE 30 WESTERN EUROPE: CHRONIC DISEASE MANAGEMENT MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

TABLE 31 WESTERN EUROPE: CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2020–2027 (USD MILLION)

TABLE 32 EASTERN EUROPE: CHRONIC DISEASE MANAGEMENT MARKET, BY SOLUTION, 2020–2027 (USD MILLION)

TABLE 33 EASTERN EUROPE: CHRONIC DISEASE MANAGEMENT MARKET, BY DELIVERY MODE, 2020–2027 (USD MILLION)

TABLE 34 EASTERN EUROPE: CHRONIC DISEASE MANAGEMENT MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

TABLE 35 EASTERN EUROPE: CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2020–2027 (USD MILLION)

TABLE 36 ASIA-PACIFIC: CHRONIC DISEASE MANAGEMENT MARKET, BY SOLUTION, 2020–2027 (USD MILLION)

TABLE 37 ASIA-PACIFIC: CHRONIC DISEASE MANAGEMENT MARKET, BY DELIVERY MODE, 2020–2027 (USD MILLION)

TABLE 38 ASIA-PACIFIC: CHRONIC DISEASE MANAGEMENT MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

TABLE 39 ASIA-PACIFIC: CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2020–2027 (USD MILLION)

TABLE 40 MIDDLE EAST & AFRICA: CHRONIC DISEASE MANAGEMENT MARKET, BY SOLUTION, 2020–2027 (USD MILLION)

TABLE 41 MIDDLE EAST & AFRICA: CHRONIC DISEASE MANAGEMENT MARKET, BY DELIVERY MODE, 2020–2027 (USD MILLION)

TABLE 42 MIDDLE EAST & AFRICA: CHRONIC DISEASE MANAGEMENT MARKET, BY APPLICATION, 2020–2027 (USD MILLION)

TABLE 43 MIDDLE EAST & AFRICA: CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2020–2027 (USD MILLION)  

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL CHRONIC DISEASE MANAGEMENT MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL CHRONIC DISEASE MANAGEMENT MARKET

FIGURE 4 GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SHARE, BY SOLUTION, 2020 (%)

FIGURE 5 GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SHARE, BY DELIVERY MODE, 2020 (%)

FIGURE 6 GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SHARE, BY APPLICATION, 2020 (%)

FIGURE 7 GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SHARE, BY END USER, 2020 (%)

FIGURE 8 GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SHARE, BY REGION, 2020 (%)

FIGURE 9 AMERICAS: CHRONIC DISEASE MANAGEMENT MARKET SHARE BY REGION, 2020 (%)

FIGURE 10 NORTH AMERICA: CHRONIC DISEASE MANAGEMENT MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 11 EUROPE: CHRONIC DISEASE MANAGEMENT MARKET SHARE, BY REGION, 2020 (%)

FIGURE 12 WESTERN EUROPE: CHRONIC DISEASE MANAGEMENT MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 13 ASIA-PACIFIC: CHRONIC DISEASE MANAGEMENT MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 14 MIDDLE EAST & AFRICA: CHRONIC DISEASE MANAGEMENT MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 15 GLOBAL CHRONIC DISEASE MANAGEMENT MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

FIGURE 16 TRIZETTO CORPORATION: KEY FINANCIALS

FIGURE 17 TRIZETTO CORPORATION: SEGMENTAL REVENUE

FIGURE 18 TRIZETTO CORPORATION: REGIONAL REVENUE

FIGURE 19 INFOSYS LIMITED: KEY FINANCIALS

FIGURE 20 INFOSYS LIMITED: SEGMENTAL REVENUE

FIGURE 21 INFOSYS LIMITED: REGIONAL REVENUE

FIGURE 22 PEGASYSTEMS INC.: KEY FINANCIALS

FIGURE 23 PEGASYSTEMS INC.: SEGMENTAL REVENUE

FIGURE 24 PEGASYSTEMS INC.: REGIONAL REVENUE

FIGURE 25 SIEMENS HEALTHCARE: KEY FINANCIALS

FIGURE 26 SIEMENS HEALTHCARE: SEGMENTAL REVENUE

FIGURE 27 SIEMENS HEALTHCARE: REGIONAL REVENUE

FIGURE 28 KONINKLIJKE PHILIPS N.V.: KEY FINANCIALS

FIGURE 29 KONINKLIJKE PHILIPS N.V.: SEGMENTAL REVENUE

FIGURE 30 KONINKLIJKE PHILIPS N.V.: REGIONAL REVENUE

FIGURE 31 EXL HEALTHCARE: KEY FINANCIALS

FIGURE 32 EXL HEALTHCARE: SEGMENTAL REVENUE

FIGURE 33 EXL HEALTHCARE: REGIONAL REVENUE

FIGURE 34 HARMONY INFORMATION SYSTEMS, INC.: KEY FINANCIALS

FIGURE 35 HARMONY INFORMATION SYSTEMS, INC.: SEGMENTAL REVENUE

FIGURE 36 HARMONY INFORMATION SYSTEMS, INC.: REGIONAL REVENUE

FIGURE 37 SCIENCESOFT USA CORPORATION.: KEY FINANCIALS

FIGURE 38 SCIENCESOFT USA CORPORATION.: SEGMENTAL REVENUE

FIGURE 39 SCIENCESOFT USA CORPORATION.: REGIONAL REVENUE